Zacks Research Issues Positive Estimate for Humana Earnings

Humana Inc. (NYSE:HUMFree Report) – Equities research analysts at Zacks Research upped their Q1 2025 EPS estimates for Humana in a research report issued on Tuesday, February 25th. Zacks Research analyst D. Chatterjee now expects that the insurance provider will post earnings per share of $9.91 for the quarter, up from their previous forecast of $6.37. The consensus estimate for Humana’s current full-year earnings is $16.47 per share. Zacks Research also issued estimates for Humana’s Q2 2025 earnings at $5.31 EPS, Q3 2025 earnings at $2.87 EPS, Q4 2025 earnings at ($1.85) EPS, Q2 2026 earnings at $4.29 EPS, Q4 2026 earnings at ($2.41) EPS and FY2026 earnings at $10.92 EPS.

Other research analysts also recently issued reports about the company. StockNews.com upgraded Humana from a “hold” rating to a “buy” rating in a research report on Tuesday. Piper Sandler boosted their price target on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and upped their price objective for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Nineteen analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $285.68.

Read Our Latest Analysis on Humana

Humana Stock Performance

Shares of HUM opened at $261.49 on Friday. Humana has a 12-month low of $213.31 and a 12-month high of $406.46. The stock has a market cap of $31.55 billion, a P/E ratio of 26.28, a PEG ratio of 2.05 and a beta of 0.56. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The company has a 50-day moving average of $270.64 and a two-hundred day moving average of $287.87.

Humana (NYSE:HUMGet Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.35%. Humana’s payout ratio is currently 35.58%.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.32% of the company’s stock.

Institutional Trading of Humana

Large investors have recently modified their holdings of the business. Creative Financial Designs Inc. ADV grew its stake in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after purchasing an additional 61 shares in the last quarter. FPC Investment Advisory Inc. acquired a new position in shares of Humana in the 4th quarter valued at approximately $27,000. Centricity Wealth Management LLC purchased a new position in shares of Humana during the 4th quarter valued at approximately $30,000. Ashton Thomas Securities LLC acquired a new stake in shares of Humana during the third quarter worth approximately $31,000. Finally, LFA Lugano Financial Advisors SA increased its stake in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

(Get Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.